NCT06084845 2024-07-25Testing the Addition of an Investigational Drug, Xevinapant, to Usual Radiation Therapy Plus Cisplatin/Carboplatin for Patients With Head and Neck CancerEastern Cooperative Oncology GroupPhase 2 Withdrawn